Close Menu

NEW YORK – Invitae announced on Sunday preliminary 2019 revenues of around $216 million, representing 45 percent growth over $147.7 million the prior year but falling short of the consensus Wall Street estimate of $219.9 million and short of its own annual revenue projections of $220 million.  

The company said testing volume grew 60 percent year over year to more than 482,000 samples compared to 303,000 samples in 2018. The company had previously projected that it would accession more than 500,000 samples in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.